title: Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry.
abstract: An analytical method was developed for the quantification of tezosentan in human plasma obtained in clinical studies. The method was linear in the range 1 to 512 ng/ml. After liquid-liquid extraction, the samples were analyzed by reversed-phase HPLC with tandem mass spectrometry. The limit of quantification was 1 ng/ml and the extraction recovery was at least 88.2%. Intra- and inter-assay coefficients of variation were below 10%. Stability tests revealed that tezosentan is stable under the different conditions tested.
authors.affiliation: Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 18, 4123 Allschwil, Switzerland. paul.vangiersbergen@actelion.com
authors.forename: Paul L M
authors.initials: PL
authors.lastname: van Giersbergen
authors.forename: Peter
authors.initials: P
authors.lastname: Wipfli
authors.forename: Jasper
authors.initials: J
authors.lastname: Dingemanse
mesh_terms: D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D065128:Endothelin Receptor Antagonists; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D011725:Pyridines / Q000097:blood*; D012680:Sensitivity and Specificity; D013777:Tetrazoles / Q000097:blood*
chemical_list: D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D013777:Tetrazoles; C120582:tezosentan